CN114805196A - 用于mr分子成像的基于锰的螯合缀合物 - Google Patents

用于mr分子成像的基于锰的螯合缀合物 Download PDF

Info

Publication number
CN114805196A
CN114805196A CN202210363484.0A CN202210363484A CN114805196A CN 114805196 A CN114805196 A CN 114805196A CN 202210363484 A CN202210363484 A CN 202210363484A CN 114805196 A CN114805196 A CN 114805196A
Authority
CN
China
Prior art keywords
iii
alkyl
compound
group
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210363484.0A
Other languages
English (en)
Chinese (zh)
Inventor
埃里克·M·盖尔
P·卡拉万
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN114805196A publication Critical patent/CN114805196A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/76—Metal complexes of amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/61—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Primary Health Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
CN202210363484.0A 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物 Pending CN114805196A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562204519P 2015-08-13 2015-08-13
US62/204,519 2015-08-13
US201662356732P 2016-06-30 2016-06-30
US62/356,732 2016-06-30
PCT/US2016/046874 WO2017027834A1 (en) 2015-08-13 2016-08-12 Manganese-based chelate conjugates for molecular mr imaging
CN201680054836.7A CN108136053B (zh) 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680054836.7A Division CN108136053B (zh) 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物

Publications (1)

Publication Number Publication Date
CN114805196A true CN114805196A (zh) 2022-07-29

Family

ID=57984258

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210363484.0A Pending CN114805196A (zh) 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物
CN202210364662.1A Pending CN114890941A (zh) 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物
CN201680054836.7A Active CN108136053B (zh) 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210364662.1A Pending CN114890941A (zh) 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物
CN201680054836.7A Active CN108136053B (zh) 2015-08-13 2016-08-12 用于mr分子成像的基于锰的螯合缀合物

Country Status (6)

Country Link
US (2) US10835623B2 (https=)
EP (1) EP3334464B1 (https=)
JP (4) JP7523883B2 (https=)
CN (3) CN114805196A (https=)
ES (1) ES2987778T3 (https=)
WO (1) WO2017027834A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7523883B2 (ja) * 2015-08-13 2024-07-29 ザ ジェネラル ホスピタル コーポレイション 分子ｍｒイメージング用マンガン系キレートコンジュゲート
CN108888781B (zh) * 2018-06-27 2021-08-06 华东理工大学 一种超分子聚电解质胶束磁共振成像造影剂的制备方法
US11267832B2 (en) 2018-10-22 2022-03-08 The Board Of Regents Of The University Of Texas System Mn(II)-based sensors to detect zinc in vivo with MRI
CN112540095B (zh) * 2019-09-20 2022-03-22 华中农业大学 酶促低场核磁共振免疫传感器检测食源性致病菌的方法
IL293875A (en) * 2019-12-17 2022-08-01 Massachusetts Gen Hospital Highly effective myeloperoxidase-activatable imaging agents
CN113248422B (zh) * 2020-02-10 2022-07-12 河南工业大学 一种手性α-氮杂芳烃四级碳中心类化合物、其制备方法及应用
US20230406873A1 (en) * 2020-11-17 2023-12-21 The General Hospital Corporation Probes, systems, and methods for magnetic resonance ph sensing
WO2022235768A1 (en) 2021-05-04 2022-11-10 Sachem, Inc. Strong binding metal-chelating resins
WO2022235769A1 (en) 2021-05-04 2022-11-10 Sachem, Inc. Strong binding metal-chelating resins using macrocycle molecules
WO2024086331A1 (en) * 2022-10-21 2024-04-25 The General Hospital Corporation Iron based mri probes
CN119499407B (zh) * 2024-11-25 2026-04-07 中国科学院精密测量科学与技术创新研究院 一种Fe基T7肽靶向脑胶质瘤小分子磁共振造影剂及其制备合成方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4889931A (en) 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
JP2772875B2 (ja) * 1991-05-14 1998-07-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法及び写真用漂白定着組成物
AU4562693A (en) 1992-07-01 1994-01-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Contrast agents for mr diagnosis
DE69502796T2 (de) * 1994-10-20 1998-10-01 Fuji Photo Film Co Ltd Neuer Eisen-Komplex, Verfahren zu seiner Herstellung, photographische Verarbeitungslösung und photographisches Verarbeitungsverfahren unter Verwendung dieses Komplexes
JP3437013B2 (ja) * 1994-10-20 2003-08-18 富士写真フイルム株式会社 新規な鉄錯体、その製造方法、写真用処理組成物およびその処理方法
TW319763B (https=) 1995-02-01 1997-11-11 Epix Medical Inc
DE19603033A1 (de) 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
CA2257891A1 (en) * 1996-06-19 1997-12-24 Roelant Mathijs Hermant Bleach activation by an iron catalyst comprising a polydentate ligand containing at least six heteroatoms
DE60012485T2 (de) 1999-02-18 2005-08-18 The Regents Of The University Of California, Oakland Salicylamid-lanthanid komplexe zur verwendung als lumineszenzmarker
CA2371816C (en) 1999-02-18 2010-04-27 The Regents Of The University Of California Phthalamide-lanthanide complexes for use as luminescent markers
DE60021545T2 (de) * 1999-04-01 2006-03-02 Unilever N.V. Zusammensetzung und verfahren zum bleichen eines substrats
EP1203026A4 (en) 1999-07-29 2005-03-16 Dyax Corp BINDING CENTERS FOR FIBRIN
IL147854A0 (en) 1999-07-29 2002-08-14 Epix Medical Inc Multimeric compounds, contrast agents containing the same and diagnostic methods utilizing the same
US6277841B1 (en) * 2000-03-02 2001-08-21 Mallinckrodt Inc. Quinoline ligands and metal complexes for diagnosis and therapy
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
US6549798B2 (en) 2001-02-07 2003-04-15 Epix Medical, Inc. Magnetic resonance angiography data
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US6869591B2 (en) 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
FR2856689A1 (fr) 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
FR2890657B1 (fr) * 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
US8034898B2 (en) 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
CN101558081B (zh) 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
JP5677026B2 (ja) * 2009-10-28 2015-02-25 住友化学株式会社 多座配位子金属錯体
WO2011100829A1 (en) * 2010-02-19 2011-08-25 Nordion (Canada) Inc. Bifunctional chelating agents
ES2634146T3 (es) * 2012-09-24 2017-09-26 Qi Wang Quelatos, agentes quelantes, sus derivados conjugados y su uso
PL2941434T3 (pl) * 2013-01-07 2021-09-06 The General Hospital Corporation Środki kontrastujące na bazie manganu do rezonansu magnetycznego
US20140350256A1 (en) * 2013-05-21 2014-11-27 University Of Southern Denmark Iron and manganese complexes comprising hexadentate monocarboxylato-containing ligands and their use for the catalysis of oxidation reactions
WO2015085005A1 (en) * 2013-12-03 2015-06-11 The General Hospital Corporation Molecular imaging probes
AR104939A1 (es) 2015-06-10 2017-08-23 Chemsenti Ltd Método oxidativo para generar dióxido de cloro
US10233205B2 (en) 2015-08-07 2019-03-19 Auburn University Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species
JP7523883B2 (ja) * 2015-08-13 2024-07-29 ザ ジェネラル ホスピタル コーポレイション 分子ｍｒイメージング用マンガン系キレートコンジュゲート

Also Published As

Publication number Publication date
ES2987778T3 (es) 2024-11-18
EP3334464A1 (en) 2018-06-20
JP2018523671A (ja) 2018-08-23
JP2022017285A (ja) 2022-01-25
CN108136053B (zh) 2022-05-27
HK1253745A1 (zh) 2019-06-28
US10835623B2 (en) 2020-11-17
CN114890941A (zh) 2022-08-12
JP2026048654A (ja) 2026-03-17
EP3334464A4 (en) 2019-01-16
JP7482099B2 (ja) 2024-05-13
US11400171B2 (en) 2022-08-02
CA2995210A1 (en) 2017-02-16
JP2024026077A (ja) 2024-02-28
JP7523883B2 (ja) 2024-07-29
WO2017027834A1 (en) 2017-02-16
US20190001003A1 (en) 2019-01-03
CN108136053A (zh) 2018-06-08
HK1257089A1 (en) 2019-10-11
EP3334464B1 (en) 2024-04-10
US20210015948A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP7482099B2 (ja) 分子ｍｒイメージング用マンガン系キレートコンジュゲート
Jacques et al. High-relaxivity magnetic resonance imaging contrast agents part 2: Optimization of inner-and second-sphere relaxivity
CN102639152B (zh) 锰螯合物及其作为磁共振成像(mri)中造影剂的用途
Tripepi et al. Synthesis of high relaxivity gadolinium AAZTA tetramers as building blocks for bioconjugation
JP2020520998A (ja) 鉄（ｉｉｉ）ｍｒｉ造影剤として使用するための化合物
Yang et al. An intravascular MRI contrast agent based on Gd (DO3A-Lys) for tumor angiography
EP1434768A1 (en) Enhanced substrate imaging by reversible binding to a paramagnetic complex
HK40072595A (en) Manganese-based chelate conjugates for molecular mr imaging
HK40078341A (en) Manganese-based chelate conjugates for molecular mr imaging
US20240285808A1 (en) Molecular probes for in vivo detection of aldehydes
HK1253745B (en) Manganese-based chelate conjugates for molecular mr imaging
CA2995210C (en) Manganese-based chelate conjugates for molecular mr imaging
CN112189014B (zh) 具有开关核磁共振造影增强的膀胱癌光动力治疗剂
HK1257089B (en) Manganese-based chelate conjugates for molecular mr imaging
Ozaki et al. Synthesis, in vitro and in vivo studies of Gd-DTPA-XDA-D1-Glc (OH) complex as a new potential MRI contrast agent
Gambino et al. A new ditopic Gd complex functionalized with an adamantyl moiety as a versatile building block for the preparation of supramolecular assemblies.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072595

Country of ref document: HK